Japan· JP-2290405G3027
オマリズマブ（遺伝子組換え）［オマリズマブ後続１］
A medicinal product containing オマリズマブ（遺伝子組換え）［オマリズマブ後続１］, registered in Japan by セルトリオン・ヘルスケア・ジャパン, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- オマリズマブ（遺伝子組換え）［オマリズマブ後続１］
- Manufacturer
- セルトリオン・ヘルスケア・ジャパン
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
オマリズマブ（遺伝子組換え）［オマリズマブ後続１］ in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOMLYCLOCelltrion Healthcare Hungary Kft., Budapest
- FinlandOmlycloCelltrion Healthcare Hungary Kft.
- SwedenOmlyclo 150 mg Injektionsvätska, lösning i förfylld injektionspennaCelltrion Healthcare Hungary Kft
- BelgiumOmlyclo 150 mgCelltrion Healthcare Hungary
- PolandOmlycloCelltrion Healthcare Hungary Kft.
- IcelandOmlycloCelltrion Healthcare Hungary Kft.
- FranceOMLYCLO 150 mg, solution injectable en seringue préremplieCELLTRION HEALTHCARE HUNGARY (HONGRIE)
- United KingdomOmlyclo 150mg/1ml solution for injection pre-filled pensCelltrion Healthcare UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omlyclo, Xolair
- Liechtenstein · Omlyclo, Xolair
- Norway · Omlyclo, Xolair
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e6a7a5ec-5e5a-49a7-8dc0-40d543508a71 GET /v1/drugs/e6a7a5ec-5e5a-49a7-8dc0-40d543508a71?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "７５ｍｇ０．５ｍＬ１キット",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2290405G3027",
"category": "注射薬",
"price_yen": 8510,
"generic_name": "オマリズマブ（遺伝子組換え）［オマリズマブ後続１］",
"product_name_jp": null,
"therapeutic_class": "2290",
"transitional_expiry": "8510"
}See everything about オマリズマブ（遺伝子組換え）［オマリズマブ後続１］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.